Figure 5. Enhanced NK and γδ T cell cytotoxicity against low-dose bortezomib-treated MM cells correlated with the interactions between NKG2D and DNAM-1 receptors and their ligands.

Increased NK cell and γδ T cell killing was abolished by blocking NKG2D or DNAM-1 on NK cells (A) and γδ T cells (B). (*p < 0.05; **p < 0.01; ***p < 0.001; ns: not significant).